Who are Lamivudine+Oxymatrine Capsules's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lamivudine-oxymatrine-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lamivudine+Oxymatrine Capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lamivudine+Oxymatrine Capsules (Lamivudine+Oxymatrine Capsules) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor + herbal immunomodulator. Area: Virology / Hepatology.

marketed Nucleoside reverse transcriptase inhibitor + herbal immunomodulator Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific) Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Lamivudine+Oxymatrine Capsules (Lamivudine+Oxymatrine Capsules) — Southeast University, China. Lamivudine inhibits reverse transcriptase to suppress viral replication, while oxymatrine provides immunomodulatory and hepatoprotective effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lamivudine+Oxymatrine Capsules TARGET	Lamivudine+Oxymatrine Capsules	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor + herbal immunomodulator	Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor + herbal immunomodulator class)

Southeast University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamivudine+Oxymatrine Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/lamivudine-oxymatrine-capsules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab